Key Takeaway: BeOne Medicines has announced positive Phase 3 results for BRUKINSA, indicating its effectiveness as a first-line treatment for mantle cell lymphoma. This development suggests a significant advancement in therapeutic options for patients. The results may enhance the drug's market position and patient outcomes.
Price reaction · baseline $284.97 (2026-06-30 close) · hit after-hours · clean, no other ONC news in the window
day 0 close · peak
+2%
Market Sentiment Analysis
POSITIVE FACTORS
BeOne Medicines reports positive Phase 3 results.
BRUKINSA shows effectiveness in first-line treatment.
Potential for improved patient outcomes in mantle cell lymphoma.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+15%
120-day peak, hindsight
Typical move
3.8%
average across 5 past catalysts
Lead asset
Tislelizumab
Phase 3 · Non-small Cell Lung Cancer
Full Press Release Details
SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd.(Nasdaq: ONC; HKEX: 06160; SSE: 688235), een bedrijf dat wereldwijd actief is op het gebied van oncologie, heeft vandaag positieve voorlopige resultaten bekendgemaakt van het fase 3-onderzoek MANGROVE (BGB-3111-306;NCT04002297. In de studie werd de toonaangevende BTK-remmer BRUKINSA®(zanubrutinib) in combinatie met rituximab vergeleken met bendamustine in combinatie met rituximab (BR) bij volwassen patiënten met niet eerder behandeld mantelcellymfoom (MCL).
Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.
Frequently Asked Questions
What are the Phase 3 results for BRUKINSA?
BeOne Medicines announced positive Phase 3 results for BRUKINSA.
What condition is BRUKINSA used to treat?
BRUKINSA is used for the first-line treatment of mantle cell lymphoma.
Who is BeOne Medicines?
BeOne Medicines is a biopharmaceutical company focused on oncology.
What is mantle cell lymphoma?
Mantle cell lymphoma is a type of non-Hodgkin lymphoma affecting B-cells.